AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06174935
Drug: 0.01% atropine ophthalmic drop
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.01% atropine ophthalmic drop will be applied daily to the affected eye
Trial: NCT06370442
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal dexmedetomidine, 100mcg
Trial: NCT06370442
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg IV
Trial: NCT06370442
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg IV
Trial: NCT05329168
Drug: Tonabacase (LSVT-1701)
RxNorm normalized name: Tonabacase
DrugBank: Tonabacase (DB17964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 or 6.0 mg/kg IV once daily for 4 days
Trial: NCT04855045
Drug: sepofarsen
RxNorm normalized name: Sepofarsen
DrugBank: Sepofarsen (DB16327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA antisense oligonucleotide for intravitreal injection
Trial: NCT04970719
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
Trial: NCT04970719
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: and 6 mg\* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
Trial: NCT04970719
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
Trial: NCT05219838
Drug: Lu AG06466
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AG06466 will be administered per dose and schedule specified in the arm description.
Trial: NCT04994704
Drug: Remimazolam group
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
Trial: NCT05442450
Drug: oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
Trial: NCT04969705
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) .
Trial: NCT06349122
Drug: Azithromycine
RxNorm normalized name: Azithromycine
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)
Trial: NCT06349122
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
Trial: NCT06349122
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole ovules: In case of Trichomonas vaginalis infection during the 1st trimester of pregnancy: 1 ovule morning and evening for 14 days (French Society of Dermatology Recommendations 2016); Metronidazole 500 mg tablets in case of Trichomonas vaginalis infection during the 2nd or the 3rd trimester of pregnancy in a single dose of 2 g
Trial: NCT06349122
Drug: Clotrimazole, Vaginal
RxNorm normalized name: Clotrimazole, Vaginal
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In case of Candida albicans infection in a single dose to be repeated up to 6 times if necessary.
Trial: NCT04967625
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A humanized anti-PD-1 monoclonal antibody
Trial: NCT04967625
Drug: Anlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2
Trial: NCT04570345
Drug: ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • Drug: ticagrelor monothearpy after first 3 months dual therapy
Trial: NCT04570345
Drug: Aspirin with P2Y12 receptor inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • Drug: aspirin plus ticagrelor dual therapy during 12 months
Trial: NCT05100719
Drug: alverine-citrate + simethicone and lactase
RxNorm normalized name: alverine citrate
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
Trial: NCT05100719
Drug: alverin-citrate + simethicone with placebo
RxNorm normalized name: alverine citrate
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
Trial: NCT06543563
Drug: esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After the craniotomy, a continuous infusion of ketamine at a rate of 0.3 mg/kg/h (0.3 ml/kg/h) is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
Trial: NCT06445400
Drug: BL-M07D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06445400
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06445400
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT04878016
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
Trial: NCT04878016
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
Trial: NCT00178451
Drug: Abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05736419
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
Trial: NCT05736419
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus will be administered beginning on day +5
Trial: NCT05736419
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
Trial: NCT05736419
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
Trial: NCT05736419
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
Trial: NCT05736419
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab on days -71, -58, -43, and -30.
Trial: NCT06387628
Drug: LM-108
RxNorm normalized name: LM-030
DrugBank: LM-030 (DB18283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM-108, 10mg/kg, d1, q6w
Trial: NCT06387628
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab, 240 mg, d1, q3w
Trial: NCT06387628
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin 1.4 mg/m2, d1, 8 , q3w
Trial: NCT06387628
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab paclitaxel 125 mg/m2, d1, 8 , q3w
Trial: NCT04696393
Drug: Mitapivat tablet
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT06546540
Drug: Telitacicept
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg，once weekly
Trial: NCT00513201
Drug: lyspro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04803747
Drug: Tranexamic acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
Trial: NCT04803747
Drug: Placebo (0.9 % Saline)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
Trial: NCT04893525
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
Trial: NCT04731259
Drug: ATR-04
RxNorm normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.
Trial: NCT05478382
Drug: Pregabalin 25 MG
RxNorm normalized name: pregabalin 25 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.
Trial: NCT04603742
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
Trial: NCT04924140
Drug: Aducanumab
RxNorm normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT05372887
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Trial: NCT04976595
Drug: Natesto
RxNorm normalized name: Natesto
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
Trial: NCT05317507
Drug: CBD oil
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg
Trial: NCT05317507
Drug: CBD oil
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg CBD
Trial: NCT05280197
Drug: liposomal bupivacaine plus free bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAP block using liposomal bupivacaine plus free bupivacaine
Trial: NCT05321706
Drug: Dapagliflozin 10 mg
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
Trial: NCT04477525
Drug: Bupivacaine Injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 cc of 0.25% bupivacaine will be injected
Trial: NCT04572256
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
Trial: NCT04947514
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
Trial: NCT04695704
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg oral montelukast once daily for 28 days
Trial: NCT04781647
Drug: ETV
RxNorm normalized name: Metvixia
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive ETV 0.5 mg tablets orally once daily
Trial: NCT00003564
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
Trial: NCT00003564
Drug: Procarbazine Hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.
Trial: NCT05196971
Drug: HS-10345 84mg
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
Trial: NCT00002264
Drug: Cryptosporidium Immune Whey Protein Concentrate (Bovine)
RxNorm normalized name: whey protein hydrolysate
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04399343
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
Trial: NCT05614518
Drug: Sodium Fluoride F-18 Injection
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject was given 5-10 mCi intravenously. Images were collected 90-120 min after injection.
Trial: NCT05396937
Drug: Atezolizumab Injection [Tecentriq]
RxNorm normalized name: atezolizumab Injection [Tecentriq]
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
Trial: NCT05396937
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
Trial: NCT05331469
Drug: NPH basal insulin titration
RxNorm normalized name: INSULIN,NPH,BEEF
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
Trial: NCT06371586
Drug: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
Trial: NCT04845490
Drug: Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
Trial: NCT04845490
Drug: Lobaplatin
RxNorm normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
Trial: NCT05470270
Drug: Hydroxycarbamide
RxNorm normalized name: Hydroxycarbamide
DrugBank: Hydroxyurea (DB01005)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
Trial: NCT05540743
Drug: biologic DMARDs
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: follow up the clinical response in Egyptian population to the drug
Trial: NCT05819853
Drug: Semaglutide Injectable Product (Wegovy and/or Ozempic)
RxNorm normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
Trial: NCT05354713
Drug: NVP-1805
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-1805 (80/10/20.8mg)
Trial: NCT05354713
Drug: NVP-1805-R1 and NVP-1805-R2
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
Trial: NCT06152523
Drug: Monalizumab/MEDI5257
DrugBank: Monalizumab (DB12824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer